TRGV9 and infection: IDLV-Env vaccination induced functional antibodies targeting multiple epitopes on the HIV-1 envelope as shown by the ability to block mAbs with different specificities, including anti-V2 and anti-CD4bs mAbs, and the ability to mediate ADCC, shown to correlate with a decreased risk of infection in the RV144 vaccine trial.3,4